+1 877 705 191424 / 7
HIPAA Compliant
ISO 27001 Certified

Completed

Phase 3
Age: 6Years - 17Years
All Genders
ID04699604

A Histamine Pharmacodynamic Biomarker to Guide Treatment in Pediatric Asthma

Led by Bridgette Jones · Updated on 2026-07-01

55

Participants Needed

1

Research Sites

1 weeks

Total Duration

AI-Summary

What this Trial Is About

This is a randomized, double-blind, placebo-controlled, crossover study comparing asthma control post treatment in African American/Black and Caucasian/White children in both hyper and hypo responsive HILD (Histamine Lontophoresis with Laser Doppler monitoring) phenotypes with uncontrolled persistent allergic asthma using Levocetirizine (LTZ) vs placebo.

CONDITIONS

Brief Title

A Histamine Pharmacodynamic Biomarker to Guide Treatment in Pediatric Asthma (HAS3)

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here